Shares Magazine
136.00p-2.20 (-1.59%)22 Jul 2025, 16:35
Jump to:
Puretech Health PLC Fundamentals
| Company Name | Puretech Health PLC | Last Updated | 2025-07-22 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 240.254 m | Market Cap | £326.75 m |
| PE Ratio | 8.83 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | $0.21 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0371 | Debt Equity Ratio | 0.0354 |
| Asset Equity Ratio | 1.4773 | Cash Equity Ratio | 0.9004 |
| Quick Ratio | 9.1865 | Current Ratio | 9.33 |
| Price To Book Value | 1.0740 | ROCE | 0 |
Puretech Health PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Puretech Health PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $15.13 m | $19.36 m | $37.24 m |
| Intangible Assets | $601,000.00 | $906,000.00 | $831,000.00 |
| Investments | $193.82 m | $321.03 m | $261.04 m |
| Total Fixed Assets | $216.38 m | $346.77 m | $316.45 m |
| Stocks | 0 | 0 | 0 |
| Debtors | $12.90 m | $2.38 m | $11.87 m |
| Cash & Equivalents | $367.31 m | $327.14 m | $350.10 m |
| Other Assets | $6.83 m | $5.48 m | $17.35 m |
| Total Assets | $602.63 m | $693.97 m | $702.65 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $41.39 m | $51.37 m | $96.89 m |
| Creditors after 1 year | $153.31 m | $184.37 m | $58.17 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $194.70 m | $235.74 m | $155.06 m |
| Net assets | $407.93 m | $458.23 m | $547.59 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $4.86 m | $5.46 m | $5.46 m |
| Share Premium | $290.26 m | $290.26 m | $289.62 m |
| Profit / Loss | $23.77 m | -$36.10 m | -$92.78 m |
| Other Equity | $414.71 m | $464.07 m | $542.22 m |
| Preference & Minorities | -$6.77 m | -$5.83 m | $5.37 m |
| Total Capital Employed | $407.93 m | $458.23 m | $547.59 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.03 | $0.04 | $0.06 |
| Debt-to-Equity | $0.04 | $0.04 | $0.06 |
| Assets / Equity | 1.4773 | 1.4773 | 1.4773 |
| Cash / Equity | 0.9004 | 0.9004 | 0.9004 |
| EPS | -$0.23 | -$0.65 | -$0.52 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -$134.37 m | -$105.92 m | -$178.79 m |
| Cashflow before financing | -$151.33 m | -$27.78 m | -$208.62 m |
| Increase in Cash | $89.56 m | $41.22 m | -$315.84 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $4.32 m | $750,000.00 | $2.09 m |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -$136.09 m | -$146.20 m | -$197.81 m |
| Pre-Tax profit | $23.77 m | -$36.10 m | -$92.78 m |
Puretech Health PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities. |
| Latest Interim Date | 28 Aug 2024 |
| Latest Fiscal Year End Date | 30 Apr 2025 |
Puretech Health PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2020-08-27 | Dr. Bennett M. Shapiro | Non-Executive Director |
| 2025-07-16 | Dr. Bharatt M. Chowrira | Executive Director,Chief Executive Officer |
| 2025-07-04 | Dr. John L. LaMattina, PhD | Non-Executive Director |
| 2025-07-04 | Dr. Robert S. Langer, Sc.D. | Non-Executive Director |
| 2025-07-04 | Dr. Raju S. Kucherlapati | Non-Executive Director,Chairman |
| 2019-09-09 | Mr. Joichi Ito | Non-Executive Director,Chairman |
| 2022-12-28 | Dame Marjorie Morris Scardino | Non-Executive Director,Senior Independent Director |
| 2024-04-25 | Mr. Christopher Viehbacher | Non-Executive Director,Chairman |
| 2025-07-04 | Ms. Kiran Mazumdar Shaw | Non-Executive Director |
| 2024-04-09 | Ms. Daphna Zohar | Executive Director,Chief Executive Officer |
| 2021-01-29 | Mr. Stephen Muniz | Executive Director,Chief Operating Officer and Company Secretary |
| 2025-07-04 | Ms. Sharon Barber-Lui | Non-Executive Director |
Puretech Health PLC Contact Details
| Company Name | PureTech Health PLC |
|---|---|
| Address | 6 St Andrew Street, 5th Floor, London, EC4A 3AE |
| Telephone | |
| Website | https://www.puretechhealth.com |
Puretech Health PLC Advisors
| Stockbroker | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
| Stockbroker | Jefferies Hoare Govett |
|---|---|
| Phone | +44 2070298000 |
| Fax | +44 2070298010 |
| Stockbroker | Numis Securities Limited |
|---|---|
| Phone | +44 2072601000 |
| Remuneration Consultant | New Bridge Street |
|---|---|
| Phone | +44 2070869341 |
| Fax | +44 2070869341 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Auditor | KPMG |
|---|---|
| Phone | +44 2073111000 |
| Fax | +44 2073113311 |
| Solicitor | DLA Piper LLP |
|---|---|
| Phone | +44 8700111111 |
| Fax | +44 2077966666 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
Market overview failed to load.
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Greencore Group PLC | 270.00 | 12.03 |
| Bakkavor Group PLC | 241.00 | 8.56 |
| Oxford Nanopore Technologies PLC | 184.60 | 5.61 |
| Compass Group PLC | 2,660.00 | 5.39 |
| Centrica PLC | 164.10 | 4.76 |
| Ocado Group PLC | 328.20 | 4.06 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Kier Group PLC | 199.80 | -4.86 |
| Raspberry Pi Holdings PLC | 445.00 | -4.01 |
| Oxford Instruments PLC | 1,916.00 | -3.52 |
| Molten Ventures PLC | 346.00 | -2.97 |
| Baltic Classifieds Group PLC | 362.50 | -2.95 |
| Just Group PLC | 129.20 | -2.86 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.